home / stock / immp / immp quote
Last: | $2.69 |
---|---|
Change Percent: | 0.74% |
Open: | $2.69 |
Close: | $2.69 |
High: | $2.77 |
Low: | $2.6 |
Volume: | 193,475 |
Last Trade Date Time: | 06/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.69 | $2.69 | $2.69 | $2.77 | $2.6 | 193,475 | 06-17-2024 |
$2.71 | $2.75 | $2.71 | $2.79 | $2.68 | 129,648 | 06-14-2024 |
$2.73 | $2.65 | $2.73 | $2.75 | $2.62 | 128,437 | 06-13-2024 |
$2.56 | $2.77 | $2.56 | $2.77 | $2.46 | 311,961 | 06-12-2024 |
$2.71 | $2.7 | $2.71 | $2.74 | $2.5901 | 163,707 | 06-11-2024 |
$2.64 | $2.7 | $2.64 | $2.7085 | $2.565 | 395,763 | 06-10-2024 |
$2.67 | $2.85 | $2.67 | $2.85 | $2.65 | 121,472 | 06-07-2024 |
$2.85 | $2.65 | $2.85 | $2.86 | $2.61 | 387,318 | 06-06-2024 |
$2.62 | $2.68 | $2.62 | $2.7 | $2.45 | 1,200,482 | 06-05-2024 |
$2.98 | $2.93 | $2.98 | $3.05 | $2.87 | 180,510 | 05-31-2024 |
$2.87 | $2.8 | $2.87 | $2.92 | $2.77 | 185,945 | 05-30-2024 |
$2.8 | $2.81 | $2.8 | $2.95 | $2.78 | 206,908 | 05-29-2024 |
$2.85 | $2.89 | $2.85 | $2.94 | $2.81 | 157,782 | 05-28-2024 |
$2.84 | $2.99 | $2.84 | $3.12 | $2.6705 | 320,058 | 05-27-2024 |
$2.84 | $2.99 | $2.84 | $3.12 | $2.6705 | 320,058 | 05-24-2024 |
$2.99 | $3.14 | $2.99 | $3.14 | $2.9 | 242,912 | 05-23-2024 |
$3.12 | $3.21 | $3.12 | $3.27 | $3.07 | 222,100 | 05-22-2024 |
$3.23 | $3.06 | $3.23 | $3.335 | $3.05 | 221,969 | 05-21-2024 |
$3.1 | $3.08 | $3.1 | $3.16 | $2.98 | 243,432 | 05-20-2024 |
$2.96 | $3 | $2.96 | $3.0791 | $2.94 | 130,722 | 05-17-2024 |
News, Short Squeeze, Breakout and More Instantly...
Immutep Limited Company Name:
IMMP Stock Symbol:
NASDAQ Market:
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the successful completion of its institutional placement ( Placement ) and the institutional component ( Institutional Enti...
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to add...
2024-05-17 08:00:11 ET Naureen Quibria from Capital One Financial issued a price target of $10.00 for IMMP on 2024-05-17 07:10:00. The adjusted price target was set to $10.00. At the time of the announcement, IMMP was trading at $2.92. IMMP currently trades -24.74% versu...